Top in endocrinology: Tirzepatide lowers HbA1c, FDA extends CGM sensor use
Click Here to Manage Email Alerts
New data from the SURPASS trial program showed that tirzepatide lowered HbA1c in adults with type 2 diabetes receiving once-daily insulin glargine. It was the top story in endocrinology last week.
The FDA’s decision to extend the use of an implantable continuous glucose monitoring (CGM) sensor in adults with diabetes was another top story. The CGM system connects to a removable smart transmitter and mobile app displaying glucose values, trends and alerts. It was initially approved by the FDA in 2018 for use up to 90 days. The most recent approval extends the use of the implantable CGM sensor to 6 months.
Read these and more top stories in endocrinology below:
SURPASS-5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine
Adults with type 2 diabetes on treatment with insulin glargine assigned tirzepatide had greater reductions in HbA1c and body weight compared with placebo, according to data from the SURPASS trial program. Read more.
FDA extends use of implantable CGM sensor to 6 months
The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release. Read more.
Risk stratification, molecular testing among recent advances in thyroid cancer treatment
When differentiated thyroid cancer was diagnosed 2 decades ago, most patients underwent a total thyroidectomy followed by radioactive iodine, regardless of the characteristics of the thyroid tumor or the patient. Today, the treatment of thyroid cancer has been significantly altered. Read more.
FDA approves spinal cord stimulation for diabetic peripheral neuropathy chronic pain
The FDA approved the use of a spinal cord stimulation therapy for the treatment of chronic pain caused by diabetic peripheral neuropathy, according to a press release from Medtronic. Read more.
More body fat linked to lower bone density, especially in men
High levels of body fat are associated with a lower bone mineral density, with the association more pronounced in men compared with women, according to study data published in The Journal of Clinical Endocrinology & Metabolism. Read more.